Compare PSMT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSMT | IMVT |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.0B |
| IPO Year | 1997 | N/A |
| Metric | PSMT | IMVT |
|---|---|---|
| Price | $126.09 | $22.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $27.71 |
| AVG Volume (30 Days) | 153.3K | ★ 1.2M |
| Earning Date | 01-07-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 5.57 | N/A |
| EPS | ★ 4.82 | N/A |
| Revenue | ★ $5,270,094,000.00 | N/A |
| Revenue This Year | $10.66 | N/A |
| Revenue Next Year | $9.64 | N/A |
| P/E Ratio | $26.09 | ★ N/A |
| Revenue Growth | ★ 7.25 | N/A |
| 52 Week Low | $81.25 | $12.72 |
| 52 Week High | $129.16 | $29.49 |
| Indicator | PSMT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 51.45 |
| Support Level | $123.95 | $21.93 |
| Resistance Level | $129.16 | $23.51 |
| Average True Range (ATR) | 3.23 | 0.90 |
| MACD | 0.50 | -0.23 |
| Stochastic Oscillator | 75.87 | 35.16 |
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.